Small molecules that safely antagonize amyloidogenesis are desperately needed for many devastating disorders that plague humankind, including Alzheimer's and Parkinson's diseases. New work brings important mechanistic insights into how one promising candidate, (−)-epigallocatechin-3-gallate (EGCG), diverts amyloid-β and α-synuclein down innocuous folding trajectories at the expense of the deleterious states populated during amyloidogenesis.
- Blake E Roberts
- James Shorter